Nespo (darbepoetin alfa)
- Region
- 🇪🇺 EU
- Active substance
- darbepoetin alfa
- Company
- Dompé Biotec S.p.A.
- Status
- Withdrawn
- Therapeutic area
- Kidney Failure, Chronic; Anemia; Cancer
- EU approval
- Fri 08 Jun 2001
- Application
- EMEA/H/C/000333
- ATC
- B03XA02
- Official record
- www.ema.europa.eu
Indication
Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Aranesp Authorised · Amgen Europe B.V.
Follow Nespo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.